BRIEF-Silexion To Begin Phase 2/3 Pancreatic Cancer Clinical Trial In Q2 2026

Reuters
Nov 26
BRIEF-Silexion To Begin Phase 2/3 Pancreatic Cancer Clinical Trial In <a href="https://laohu8.com/S/QTWO">Q2</a> 2026

Nov 25 (Reuters) - Silexion Therapeutics Corp SLXN.O:

  • SILEXION THERAPEUTICS SUCCESSFULLY COMPLETES TOXICOLOGY STUDIES FOR SIL204, NEXT-GENERATION RNA SILENCING THERAPY, AHEAD OF PHASE 2/3 CLINICAL TRIAL IN PANCREATIC CANCER

  • SILEXION THERAPEUTICS CORP - PHASE 2/3 CLINICAL TRIAL IN PANCREATIC CANCER SET FOR Q2 2026

Source text: ID:nGNX6sntSh

Further company coverage: SLXN.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10